Literature DB >> 25786915

ALIX Rescues Budding of a Double PTAP/PPEY L-Domain Deletion Mutant of Ebola VP40: A Role for ALIX in Ebola Virus Egress.

Ziying Han1, Jonathan J Madara1, Yuliang Liu1, Wenbo Liu1, Gordon Ruthel1, Bruce D Freedman1, Ronald N Harty1.   

Abstract

Ebola (EBOV) is an enveloped, negative-sense RNA virus belonging to the family Filoviridae that causes hemorrhagic fever syndromes with high-mortality rates. To date, there are no licensed vaccines or therapeutics to control EBOV infection and prevent transmission. Consequently, the need to better understand the mechanisms that regulate virus transmission is critical to developing countermeasures. The EBOV VP40 matrix protein plays a central role in late stages of virion assembly and egress, and independent expression of VP40 leads to the production of virus-like particles (VLPs) by a mechanism that accurately mimics budding of live virus. VP40 late (L) budding domains mediate efficient virus-cell separation by recruiting host ESCRT and ESCRT-associated proteins to complete the membrane fission process. L-domains consist of core consensus amino acid motifs including PPxY, P(T/S)AP, and YPx(n)L/I, and EBOV VP40 contains overlapping PPxY and PTAP motifs whose interactions with Nedd4 and Tsg101, respectively, have been characterized extensively. Here, we present data demonstrating for the first time that EBOV VP40 possesses a third L-domain YPx(n)L/I consensus motif that interacts with the ESCRT-III protein Alix. We show that the YPx(n)L/I motif mapping to amino acids 18-26 of EBOV VP40 interacts with the Alix Bro1-V fragment, and that siRNA knockdown of endogenous Alix expression inhibits EBOV VP40 VLP egress. Furthermore, overexpression of Alix Bro1-V rescues VLP production of the budding deficient EBOV VP40 double PTAP/PPEY L-domain deletion mutant to wild-type levels. Together, these findings demonstrate that EBOV VP40 recruits host Alix via a YPx(n)L/I motif that can function as an alternative L-domain to promote virus egress.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Alix; ESCRT; Ebola; L-domain; VLPs; budding; filovirus; virus-host interaction

Mesh:

Substances:

Year:  2015        PMID: 25786915      PMCID: PMC4564528          DOI: 10.1093/infdis/jiu838

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  58 in total

1.  A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding.

Authors:  R N Harty; M E Brown; G Wang; J Huibregtse; F P Hayes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding.

Authors:  Bettina Strack; Arianna Calistri; Stewart Craig; Elena Popova; Heinrich G Göttlinger
Journal:  Cell       Date:  2003-09-19       Impact factor: 41.582

3.  Identification and structural characterization of the ALIX-binding late domains of simian immunodeficiency virus SIVmac239 and SIVagmTan-1.

Authors:  Qianting Zhai; Michael B Landesman; Howard Robinson; Wesley I Sundquist; Christopher P Hill
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

4.  The ESCRT pathway and HIV-1 budding.

Authors:  Yoshiko Usami; Sergei Popov; Elena Popova; Michio Inoue; Winfried Weissenhorn; Heinrich G Göttlinger
Journal:  Biochem Soc Trans       Date:  2009-02       Impact factor: 5.407

5.  An LYPSL late domain in the gag protein contributes to the efficient release and replication of Rous sarcoma virus.

Authors:  Kari A Dilley; Devon Gregory; Marc C Johnson; Volker M Vogt
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

6.  Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding.

Authors:  Robert D Fisher; Hyo-Young Chung; Qianting Zhai; Howard Robinson; Wesley I Sundquist; Christopher P Hill
Journal:  Cell       Date:  2007-03-09       Impact factor: 41.582

7.  Regulation of CHMP4/ESCRT-III function in human immunodeficiency virus type 1 budding by CC2D1A.

Authors:  Yoshiko Usami; Sergei Popov; Eric R Weiss; Christie Vriesema-Magnuson; Arianna Calistri; Heinrich G Göttlinger
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

8.  Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4.

Authors:  Joanna Timmins; Guy Schoehn; Sylvie Ricard-Blum; Sandra Scianimanico; Thierry Vernet; Rob W H Ruigrok; Winfried Weissenhorn
Journal:  J Mol Biol       Date:  2003-02-14       Impact factor: 5.469

9.  Potent rescue of human immunodeficiency virus type 1 late domain mutants by ALIX/AIP1 depends on its CHMP4 binding site.

Authors:  Yoshiko Usami; Sergei Popov; Heinrich G Göttlinger
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

10.  Alix serves as an adaptor that allows human parainfluenza virus type 1 to interact with the host cell ESCRT system.

Authors:  Jim Boonyaratanakornkit; Henrick Schomacker; Peter Collins; Alexander Schmidt
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more
  26 in total

1.  Conserved Mode of Interaction between Yeast Bro1 Family V Domains and YP(X)nL Motif-Containing Target Proteins.

Authors:  Yoko Kimura; Mirai Tanigawa; Junko Kawawaki; Kenji Takagi; Tsunehiro Mizushima; Tatsuya Maeda; Keiji Tanaka
Journal:  Eukaryot Cell       Date:  2015-07-06

2.  The Carboxyl Terminus of the Porcine Circovirus Type 2 Capsid Protein Is Critical to Virus-Like Particle Assembly, Cell Entry, and Propagation.

Authors:  Yang Zhan; Wanting Yu; Xiong Cai; Xinnuo Lei; Hongyu Lei; Aibing Wang; Yujie Sun; Naidong Wang; Zhibang Deng; Yi Yang
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

Review 3.  Exosomes in Viral Disease.

Authors:  Monique R Anderson; Fatah Kashanchi; Steven Jacobson
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

4.  ITCH E3 Ubiquitin Ligase Interacts with Ebola Virus VP40 To Regulate Budding.

Authors:  Ziying Han; Cari A Sagum; Mark T Bedford; Sachdev S Sidhu; Marius Sudol; Ronald N Harty
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

5.  The Integrity of the YxxL Motif of Ebola Virus VP24 Is Important for the Transport of Nucleocapsid-Like Structures and for the Regulation of Viral RNA Synthesis.

Authors:  Yuki Takamatsu; Larissa Kolesnikova; Martin Schauflinger; Takeshi Noda; Stephan Becker
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

6.  Angiomotin Counteracts the Negative Regulatory Effect of Host WWOX on Viral PPxY-Mediated Egress.

Authors:  Jingjing Liang; Gordon Ruthel; Cari A Sagum; Mark T Bedford; Sachdev S Sidhu; Marius Sudol; Chaitanya K Jaladanki; Hao Fan; Bruce D Freedman; Ronald N Harty
Journal:  J Virol       Date:  2021-02-03       Impact factor: 5.103

Review 7.  The Role of Exosomal VP40 in Ebola Virus Disease.

Authors:  Michelle L Pleet; Catherine DeMarino; Benjamin Lepene; M Javad Aman; Fatah Kashanchi
Journal:  DNA Cell Biol       Date:  2017-02-08       Impact factor: 3.311

8.  Ubiquitin Ligase WWP1 Interacts with Ebola Virus VP40 To Regulate Egress.

Authors:  Ziying Han; Cari A Sagum; Fumio Takizawa; Gordon Ruthel; Corbett T Berry; Jing Kong; J Oriol Sunyer; Bruce D Freedman; Mark T Bedford; Sachdev S Sidhu; Marius Sudol; Ronald N Harty
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

9.  A cationic, C-terminal patch and structural rearrangements in Ebola virus matrix VP40 protein control its interactions with phosphatidylserine.

Authors:  Kathryn Del Vecchio; Cary T Frick; Jeevan B Gc; Shun-Ichiro Oda; Bernard S Gerstman; Erica Ollmann Saphire; Prem P Chapagain; Robert V Stahelin
Journal:  J Biol Chem       Date:  2018-01-18       Impact factor: 5.157

10.  WWOX-Mediated Degradation of AMOTp130 Negatively Affects Egress of Filovirus VP40 Virus-Like Particles.

Authors:  Jingjing Liang; Gordon Ruthel; Bruce D Freedman; Ronald N Harty
Journal:  J Virol       Date:  2022-02-02       Impact factor: 6.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.